Presentations & Publications

A Dose-Response Study of a Novel Non-Thermal Method of Selectively Modifying Cellular Structures in Skin with Low Energy Nanosecond Electrical Stimulation

• NPS™ technology was found to provide a safe, non-thermal mechanism for targeting cellular structures with a mild inflammatory response
• Positive Caspase-3 staining at 2 and 4 hours post-NPS treatment confirms Programmed Cell Death (PCD)

Presented at American Society for Laser Medicine and Surgery Annual Meeting (2018) and received the Best of Basic Science and Translational Research Award.

view study overview >
view study poster >

First Clinical Use of Non-Thermal Nano-Pulse Stimulation™ Treatment to Eliminate Seborrheic Keratosis Lesions

• 82% of treated SK lesions rated by investigators as cleared or mostly cleared with a single NPS treatment
• Evidence to guide appropriate energy parameters and protocol design decisions for planned future clinical studies of other benign and non-benign lesions

Presented at American Society for Laser Medicine and Surgery Annual Meeting (2018).

view study overview >
view study poster >

Nano-Pulse Stimulation™ technology induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response

PloS One, 2018;13(1):e0191311

View PDF >

Profiling the immunogenic cell death (ICD) mechanisms induced by Nano-Pulse Stimulation (NPS) treatment in mouse B16-F10 melanoma tumors using NanoString technology

Poster Presentation: Society of Immunotherapy of Cancer Annual Scientific Meeting, November 2017
 
View article >

Nano-Pulse Stimulation™ technology is a physical modality that can trigger immunogenic tumor cell death

• Richard Nuccitelli  Email author
• Amanda McDaniel
• Snjezana Anand
• John Cha
• Zachary Mallon
• Jon Casey Berridge
• Darrin Uecker

Journal for ImmunoTherapy of Cancer20175:32
DOI: 10.1186/s40425-017-0234-5
©  The Author(s). 2017
 
view article >

Nanosecond pulsed electric field treatment of tumor cell lines triggers immunogenic cell death (ICD)

Poster Presentation: Society of Immunotherapy of Cancer Annual Scientific Meeting, November 2016

Nano-Pulse Stimulation treatment induced three markers of ICD in three tumor cell lines, providing a possible explanation of why in vivo NPS treatment has shown a vaccine-like effect that inhibits secondary tumor growth after subsequent challenges with tumor cells.

View PDF >

Nanosecond pulsed electric field treatment of murine melanomas initiates an immune response and inhibits metastasis.

Poster Presentation: Society of Immunotherapy of Cancer Annual Scientific Meeting, November 2016

Mice given a single melanoma tumor which were later either treated surgically or with Nano-Pulse Stimulation treatment. When subsequently challenged with intravenously injected melanoma cells, the NPS-treated mice exhibited fewer metastases than did the mice that had surgical removal, suggesting that the immune system had removed some of the melanoma cells from circulation in the NPS treated mice. This observation extends NPS’s vaccination effect beyond secondary tumor challenge to circulating cancer cells.

Adaptive immune response to Nano-Pulse Stimulation™ technology

Poster Presentation: Society of Immunotherapy of Cancer Annual Scientific Meeting, November 2016

Nano-Pulse Stimulation treated murine fibrosarcoma tumors significantly increased the infiltration of immune system cells into the treated primary tumor and three weeks later challenge tumors were completely rejected due to the production and increase in functionality of T cells.

View PDF >

Nanosecond pulsed electric field treatment of murine melanomas initiates an immune response and inhibits metastasis.

Poster Presentation: Society of Immunotherapy of Cancer Annual Scientific Meeting, November 2016

Mice given a single melanoma tumor which were later either treated surgically or with Nano-Pulse Stimulation treatment. When subsequently challenged with intravenously injected melanoma cells, the NPS-treated mice exhibited fewer metastases than did the mice that had surgical removal, suggesting that the immune system had removed some of the melanoma cells from circulation in the NPS treated mice. This observation extends NPS vaccination effect beyond secondary tumor challenge to circulating cancer cells.